Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix, Affymetrix

Premium

CombiMatrix last week launched a microarray product for the H5N1 “Bird Flu” influenza A virus. The product targets identification of the virus and allows the tracking of mutations that can occur in its genetic makeup, the company said in a statement.


Affymetrix last week launched a new line of reagents, including two new cDNA synthesis kits, developed in collaboration with Invitrogen. The product offering is a sample preparation system for gene expression analysis. The One-Cycle cDNA Synthesis Kit contains reagents necessary for standard target labeling, using a minimum of 1 microgram of total RNA prior to the IVT labeling step.

The new Two-Cycle cDNA Synthesis Kit offers a streamlined procedure for preparing samples using small amounts of materials, such as biopsy or laser-capture-dissected samples, the company said. It contains enough reagents for performing two cycles of cDNA synthesis before IVT labeling. The two-cycle dDNA protocol takes 60 hours, the company said.

 

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.